Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion

International Journal of Obesity

Volumn 37, Issue 5, 2013, Pages 693-698

  Rotondo, A ^a,b   Janssen, P ^a   Mule F ^b   Tack, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

gastric accommodation; GLP 1; intragastric pressure; liraglutide; satiation

Indexed keywords

LIRAGLUTIDE; PLACEBO;

ADULT; APPETITE; ARTICLE; BAROSTAT; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; DOSE RESPONSE; DRINKING; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; INTESTINE INNERVATION; MALE; MEAL; NAUSEA; NORMAL HUMAN; PERCEPTION; POSTPRANDIAL STATE; PRIORITY JOURNAL; SATIETY; SENSORIMOTOR FUNCTION; STOMACH PRESSURE; VOMITING;

ADULT; BEVERAGES; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EATING; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MANOMETRY; NAUSEA; POSTPRANDIAL PERIOD; PRESSURE; SATIATION; STOMACH; TREATMENT OUTCOME;

EID: 84877577610     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.101     Document Type: Article

References (36)

1. Schwartz GJ. Integrative capacity of caudal brainstem in the control of food intake. Philos Trans R Soc Lond B Biol Sci Ser B 2006; 361: 1275-1280.
2. Janssen P, Vanden Berghe P, Verschueren S, Lehmann A, Depoortere I, Tack J. Review Article: the role of gastric motility in the control of food intake. Aliment Pharmacol Ther 2011; 33: 880-894.
3. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J. Assessment of meal induced gastric accomodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003; 52: 1271-1277.
4. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103.
5. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81-86.
6. Van Dijk G, Thiele TE. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides 1999; 33: 406-414.
7. Giralt M, Vergara P. Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 1999; 44: 322-329.
8. Schirra J, Houck P, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagonlike peptide-1 (7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000; 46: 622-631.
9. Anvari M, Paterson CA, Daniel EE, McDonald TJ. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Des Sci 1998; 43: 1133-1140.
10. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998; 43: 2284-2290.
11. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282: G424-G431.
12. Andrews CN, Bharucha AE, Camilleri M, Low PA, Seide BM, Burton DD et al. Effects of glucagons-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. Neurogastroenterol Motil 2007; 19: 716-723.
13. Andrews CN, Bharucha AE, Camilleri M, Low PA, Seide B, Burton D et al. Nitrergic contribution to gastric relaxation induced by glucagons-like peptide-1 (GLP-1) in healthy adults. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1359-1365.
14. Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG et al. Pheriperal motor action of glucagon like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil 2010; 22: 664-672.
15. Rotondo A, Amato A, Lentini L, Baldassano S, Mule F. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 2011; 32: 60-64.
16. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
17. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669.
18. Mikhail NE. Is liraglutide a useful addition to diabetes therapy? Endocr Pract 2010; 16: 1028-1037.
19. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Lean ME NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo controlled study. Lancet 2009; 374: 1606-1616.
20. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. LEAD-3 (Mono) Study group. Liraglutide versus glimepiride monotherapy for the type 2 diabetes (LEAD-3 Mono): a randomized; 52-week, phase III, double blind, parallel-treatment trial. Lancet 2009; 374: 473-481.
21. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimiperide and placebo, all in combination with metformin, in type 2 diabetes. The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
22. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P et al. LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met TZD). Diabetes Care 2009; 32: 1224-1230.
23. Kapitza C, Zdravkotic M, Zijlstra E, Segel S, Heise T, Flint A. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol 2011; 51: 951-955.
24. Janssen P, Verschueren S, Ly GH, Vos R, Van Oudenhove L, Tack J. Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Mot 2011; 23: 316-322.
25. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-535.
26. Notivol R, Coffin B, Azpiroz F, Mearin F, Serra J, Malagelada JR. Gastric tone determines the sensitivity of the stomach to distention. Gastroenterology 1995; 108: 330-6.
27. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006; 55: 1685-1691.
28. Azpiroz F, Malagelada JR. Perception and reflex relaxation of the stomach in response to gut distention. Gastroenterology 1990; 98: 1193-1198.
29. Mundt MW, Hausken T, Samsom M. Effect of intragastric barostat bag on proximal and distal gastric accommodation in response to liquid meal. Am J Physiol Gastrointest Liver Physiol 2002; 283: G681-G686.
30. Van den Elzen BD, Bennink RJ, Wieringa RE, Tytgat GN, Boeckxstaens GE. Fundic accommodation assessed by SPECT scanning: comparison with the gastric barostat. Gut 2003; 52: 1548-1554.
31. Wettergren A, Maina P, Boesby S, Holst JJ. Glucagon-like peptide-1 7-36 amide and peptide YY have additive effect on gastric acid secretion in man. Scand J Gastroenterol 1997; 32: 552-555.
32. Lee KJ, Kindt S, Tack J. Pathophysiology if functional dyspepsia. Best Pract Res Clin Gastroenterol 2004; 18: 707-716.
33. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J et al. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
34. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915-1921.
35. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V et al. One week0s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
36. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429.